CS Corporate Advisors has advised Suma Capital on the acquisition of a minority stake of Ziacom .

Suma Capital is a capital equity firm focused on supporting profitable and high-growth Spanish SMEs, with majority and minority stakes, to accelerate their organic and inorganic growth plans.

Founded in 2004, Ziacom Medical is, today, one of the leading national manufacturers of medical technology in the dental sector, specializing in the design, manufacture and marketing of dental implants and abutments, biomaterials and instrumental devices.

Ziacom Medical stands out for its extensive catalog of products that has allowed it to gain the trust of a wide and balanced portfolio of clients, efficiently supplying both small and large dental clinics. The group also has its own center specializing in CAD-CAM digital technology.

The company, which has been growing annually at rates above 15%, exceeded 11 million euros in turnover in 2021, with more than 1,000 clients and an international presence in 17 countries, among which the US market stands out, where Ziacom has own headquarters and FDA approval.

This strong growth, above the sector, has been achieved in modern facilities of more than 4,000 m2, inaugurated in 2018, and thanks to an experienced and committed management team, led by Alejandro del Valle himself, who will continue to lead the day to day business.

Ziacom will have the commitment of SC Growth Fund II, a growth capital fund with a strong focus on ESG, managed by Suma Capital and with 160 million euros in capital.

With the support of Suma Capital, Ziacom’s growth strategy will focus on three basic pillars: increasing penetration in Spain, extending its leadership to other markets, mainly in southern Europe, and launching new families of products and services that allow loyalty to present and future customers.